In an interview with Life Sciences Intellectual Property Review, Partner Michael Summersgill discusses how his team achieved more favorable outcomes than others in a series of lawsuits brought by Ravgen over pre-natal screening tests.
Excerpt: “First, we came up with arguments that the other defendants didn’t; the release argument is a good example of that. In the Quest case, after a robust fact investigation, we developed an argument that—because of a provision in a licence agreement between Ravgen and another company—Ravgen had released claims for past infringement against companies like Quest and others.”